Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers.
Unrestrained oncogene activity triggers DNA damage. Cancer cells exploit various stratagems to deal with this potentially lethal event. We found that hematologic cancer cells inactivate the Hippo co-activator Yes-associated protein 1 (YAP1). A synthetic lethal approach is proposed whereby inhibition of the serine/threonine kinase 4 (STK4) could be exploited to restore YAP1 levels in hematologic cancers.
Jerome Lipper Multiple Myeloma Center; Department of Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School; Boston, MA USA; Functional Genomics of Cancer Unit; Division of Molecular Oncology; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS); San Raffaele Scientific Institute; Milan, Italy.
Francesca
F
Cottini
Jerome Lipper Multiple Myeloma Center; Department of Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School ; Boston, MA USA.
Kenneth C
KC
Anderson
Functional Genomics of Cancer Unit; Division of Molecular Oncology; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS); San Raffaele Scientific Institute ; Milan, Italy.
Giovanni
G
Tonon
STK4; YAP-1; multiple myeloma; tumor suppressor